Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 262-267

  Park, Tai Sun ^a   Kim, Hye Ryoun ^b   Koh, Jae Soo ^b   Jang, Seung Hun ^c   Hwang, Yong Il ^c   Yoon, Ho Il ^d   Chung, Jin Haeng ^d   Kim, Cheol Hyeon ^b   Kim, Sung Soo ^e   Kim, Woo Sung ^a   Jo, Jungmin ^a   Lee, Jae Cheol ^a   Choi, Chang Min ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Hallym University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Chongju University   (South Korea)

Author keywords

Adjuvant chemotherapy; Biologic markers; Heat shock protein 70; Non small cell lung cancer; Survival analysis; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; BIOLOGICAL MARKER; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908399110     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.009     Document Type: Article

References (21)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
3. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360. The International Adjuvant Lung Cancer Trial Collaborative Group.
4. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
5. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
6. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008, 26:5043-5051.
7. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
8. Arriagada R., Auperin A., Burdett S., Higgins J.P., Johnson D.H., Le Chevalier T., et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010, 375:1267-1277. NSCLC Meta-analyses Collaborative Group.
9. Tsao M.S., Sakurada A., Ding K., Aviel-Ronen S., Ludkovski O., Liu N., et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2011, 6:139-147.
10. Martin P., Leighl N.B., Tsao M.S., Shepherd F.A. KRAS Mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013, 8:530-542.
11. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
12. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368:1101-1110.
13. Gething M.J., Sambrook J. Protein folding in the cell. Nature 1992, 355:33-45.
14. Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
15. Cai M.B., Wang X.P., Zhang J.X., Han H.Q., Liu C.C., Bei J.X., et al. Expression of heat shock protein 70 in nasopharyngeal carcinomas: different expression patterns correlate with distinct clinical prognosis. J Transl Med 2012, 10:96.
16. Murphy M.E. The HSP70 family and cancer. Carcinogenesis 2013, 34:1181-1188.
17. Kiang J.G., Tsokos G.C. Heat shock protein 70kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998, 80:183-201.
18. Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007, 81:15-27.
19. Calderwood S.K. Chaperones and slow death - a recipe for tumor immunotherapy. Trends Biotechnol 2005, 23:57-59.
20. Calderwood S.K., Ciocca D.R. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int J Hyperthermia 2008, 24:31-39.
21. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403.